Lipoprotein-associated phospholipase A2 (Lp-PLA2), an enzyme expressed in atherosclerotic plaques is presented in circulation bound to LDL. As a biomarker for coronary artery disease, it has been reported that Lp-PLA2 activity is upregulated in coronary artery disease, especially in acute coronary syndrome, similar in magnitude to that with non-HDL cholesterol or systolic blood pressure. There are few reports on Lp-PLA2 activity and its association of coronary disease severity in statin user. We have studied 115 consecutive case of scheduled coronary angiography, 27 cases revealed normal coronary angiogram (NL). The others are 37 cases of stable angina (SA), 33 cases of unstable angina (UA), and 18 cases of acute myocardial infarction (MI). Lp-PLA2 activity of each group shows highest in MI group, but statistically in significant (13.5짹7.5, 18.7짹10.5, 16.2짹10.5, 24.9짹19.0 IU/ml in NL, SA, UA, and MI group, respectively) (p>0.05). We have analyzed the Lp-PLA2 activity in the subgroup, because previous statin users were included also among the case. Lp-PLA2 activity was 21.2짹14.5, 18.9짹9.1 IU/ml in statin non-user (SN) and statin user (SU), respectively (p<0.05). Even in SU, Lp-PLA2 activity was highest in MI, but the significance was lower than SN group. Additionally, Lp-PLA2 activity was well correlated to LDL level (r2=0.315, p<0.05). In conclusively, Lp-PLA2 activity is good biomarker along the coronary disease severity and this effect might be attenuated by statin.